Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon Catheters Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET INTRODUCTION

A drug-eluting balloon (DEB) Catheter is a conventional semi-compliant percutaneous transluminal coronary angioplasty (PTCA) balloon catheter. It is covered with an anti-restenotic drug released during inflation of the balloon into the vessel wall. It prevents re-narrowing of the coronary arteries. It yields short-term, homogenous, fast, local drug delivery. It promotes enhanced vessel healing and helps in reducing the need for prolonged dual antiplatelet therapy. Drug-eluting balloons (DEB) catheters are a potential alternative to combat restenosis.

MARKET DYNAMICS

The increase in geriatric population, rise in cardiovascular disease, and changes in the lifestyle of individuals lead to obesity, hypertension, and other factors that result in vascular disease are supposed to drive percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market growth. Furthermore, rising technological advancements and reclassification of catheters in FDA policy will propel the development of the market during the forecast period. The rising demand for minimally invasive surgeries, improved healthcare facilities in developing economies, and rise in disposable incomes are expected to surge the market growth. However, the availability of alternative therapies may restrain the market growth.

MARKET SCOPE

The "Percutaneous Transluminal Coronary Angioplasty Drug-Eluting Balloon Catheters Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market with detailed market segmentation by type and end-users. The percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market are expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market are segmented on the basis of type and end-users. On the basis of type, the market is segmented into paclitaxel-eluting type, and others. On the basis of end-users, the market is segmented as hospitals, clinics, and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market in these regions.

MARKET PLAYERS

The report covers key developments in the percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market are anticipated to have lucrative growth opportunities in the future with the rising demand for percutaneous transluminal coronary angioplasty drug-eluting balloon catheters in the global market. Below mentioned is the list of few companies engaged in the percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market.

The report also includes the profiles of key players in percutaneous transluminal coronary angioplasty drug-eluting balloon catheters market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

•  B. Braun Melsungen AG
  
•  Medtronic PLC
  
•  Abbott Inc.
  
•  Boston Scientific Corporation
  
•  Biotronik Se & Co.KG
  
•  Spectranetics Corporation
  
•  Cordis Corporation
  
•  ENDOCOR GmbH
  
•  CR Bard Inc
  
•  Terumo Corporation
  

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon Catheters Report Scope